Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Germany has said it “ will not give in ” and that Europe must “ respond firmly ” as US President Donald Trump targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback